
This Outdated ‘Investing Rule' Is Costing Investors Millions
Business report graph with pen and calculator and notebook
It's as predictable as night following day: Stock markets crash, and we almost immediately hear more about the so-called '60/40' investing rule as a way for investors to protect themselves.
Don't fall for this overdone 'rule of thumb' (which, as the name says, recommends putting 60% of your portfolio into stocks and 40% into bonds).
Today we're going to look at a much better way—one that pays you 9.7% dividends and delivers far better performance, too.
Today's setup reminds me of what I heard near the end of 2022, when stocks were crashing. Back then, many advisors were dredging up this old idea to help ease worried investors' fears.
Except, in doing so, they were costing those investors money, which I pointed out in an October 2022 Contrarian Outlook article: 'With the 60/40 portfolio, you're actively withdrawing money from your portfolio during a bear market, so the longer the market stays down, the more you need to gain to make your initial investment whole again.'
Here's how a garden variety S&P 500 index fund has done compared to a 60/40 ETF, the iShares Core 60/40 Balanced Allocation ETF (AOR), since then:
AOR Total Returns 2022 Forward
In other words, even with the tariff panic (which you can see at right above), investors who opted for 60/40 rule then are $1,912 poorer, as of this writing, for every $10,000 they invested than those who simply bought an S&P 500 index fund.
Now that investors are panicking again, I'm even more convinced 60/40 is a poor strategy. Let's zoom out and look at the lousy performance this rule has baked in over the long run:
AOR Long Term Returns Lag
Here we see that investors relying on 60/40 would've missed a staggering $47,120 in profits for every $10,000 invested over 16 years.
Stretch that over a lifetime, and you can see that 60/40 can literally cost you millions.
To be sure, moving cash into bonds might feel good today, with fear running high, but if you do, you will lose money compared to the average stock investor.
The 60/40 rule stems from economist Harry Markowitz's modern portfolio theory (MPT) from back in the 1950s. This work suggested investors could optimize returns, relative to risk, by diversifying across asset classes.
By the late 20th century, 60/40 was a go-to for many investors, although, as you can see from the chart above, it began badly lagging stocks in the early 21st century (it had actually begun doing this in the 1990s, but things really fell apart after the dot-com bubble burst).
Markowitz never meant this rule to be an actual guide for advisors, but it is convenient, so it's not too surprising that it's endured—even with its poor performance.
But that may be starting to change, as more pros speak out against 60/40. That may, funnily enough, speed up a stock rebound.
Just before the Trump tariff selloff began, Blackrock's Larry Fink wrote about how the rule doesn't work anymore, saying it 'may no longer fully represent true diversification.' More recently, Apollo Chief Economist Torsten Sløk wrote that the 60/40 portfolio continues to underperform, 'with only a 2% annual return for the past three and a half years.'
The question, then, becomes: What do we choose instead?
In that October 2022 article I mentioned earlier, I suggested an alternative to 60/40: three closed-end funds (CEFs) that combine stocks, corporate bonds and real estate.
This three-fund 'mini-portfolio' included the 9.5%-yielding, stock-focused Liberty All-Star Equity Fund (USA); the 11.2%-yielding, bond-focused PIMCO Corporate & Income Opportunity Fund (PTY); and the real-estate-heavy, 8.5%-yielding Cohen & Steers Quality Income Realty Fund (RQI).
Why these funds? The reason is why members of my CEF Insider service choose CEFs in the first place: income. With an average 9.7% yield as I write this, they provide a huge income stream that index funds and 60/40 simply can't match.
We have also seen, in the more than two decades since all three of these funds have been around, very consistent payouts, on average.
Because profits from stocks fluctuate (every year will give different returns), USA's dividend will tend to move around more than the more stable payouts PTY provides. Meantime, changes in income from rents, as well as fluctuating interest rates, tend to cause RQI's payouts to take a small step up or down for a few years' time.
Over the long haul, though, these payouts tend to remain roughly stable as managers move to keep them consistent.
Beyond this, though, is the performance.
CEFs Outperform
Over the last decade, these funds have delivered a 9.3% average annualized return, while 60/40 (shown in orange above) has delivered about half that.
The bottom line: These three funds have a proven history of delivering strong dividends, and they spread your money across asset classes. In other words, they do what 60/40 is supposed to—without the (potentially millions) in missed profits.
Michael Foster is the Lead Research Analyst for Contrarian Outlook. For more great income ideas, click here for our latest report 'Indestructible Income: 5 Bargain Funds with Steady 8.6% Dividends.'
Disclosure: none
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Trading Day: Teflon stocks glide higher
By Jamie McGeever ORLANDO, Florida (Reuters) - TRADING DAY Making sense of the forces driving global markets By Jamie McGeever, Markets Columnist Markets again lacked a unifying theme on Wednesday, as world stocks hit record highs, Wall Street ended mixed and Treasury yields tumbled, all against a backdrop of patchy U.S. economic data and a lack of clarity on global trade talks. In my column today I look at how, despite justifiable fears of tariff-fueled price rises later this year and beyond, the global forces of disinflation are stronger right now than the forces of inflation. More on that below, but first, a roundup of the main market moves. If you have more time to read, here are a few articles I recommend to help you make sense of what happened in markets today. 1. U.S. private payrolls post smallest gain in over twoyears in May 2. Euro needn't dethrone dollar to draw reserve flood: MikeDolan 3. Trump tax-cut bill could cost $2.4 trillion, less thanearlier forecast 4. Trump calls China's Xi tough, 'hard to make a deal with' 5. U.S. economic activity declines as tariffs pressureprices, Fed says Today's Key Market Moves * World stocks hit an all-time high, as the MSCI AllCountry index rises for a third day to 890.94 points. * The S&P 500 and Nasdaq edge higher, with the tech sectoramong the leading gainers and energy the biggest decliner. * The Canadian dollar climbs to an eight-month high of1.3650 per $ after the BoC leaves interest rates unchanged at2.75%. * Treasuries rally following a batch of weak U.S. economicdata. Longer-dated yields fall 10 bps, the steepest drop inseven weeks. * Oil falls 1%, pressured by a surprisingly large build-upin gasoline and diesel inventories. Teflon stocks glide higher Financial market moves can usually be traced to, or at least reasonably explained by, a narrative or new development that changes investors' view of the value of the asset in question. But some days, they are difficult to rationalize. Wednesday was one of those days, at least in equities. Wall Street rose for a third session, the Nasdaq climbed back into the green for the year, and global stocks rose to their highest level on record. Yet the newsflow was hardly bullish, although the nonpartisan U.S. Congressional Budget Office did lower its estimate of how much President Donald Trump's tax-cut and spending bill will add to the national debt by $1.4 trillion. On the trade front, the Trump administration doubled steel and aluminum tariffs, and it became clear that trade talks with Europe and China are proving difficult. The deadline for countries to show their "best offers" to avoid other punitive import levies taking effect next month passed on Wednesday too. China's decision in April to suspend exports of a wide range of rare earths continues to wreak havoc across crucial supply chains around the world, especially in the auto industry. Some European auto parts plants have suspended production. On the economic data front, the U.S. 'stagflation' alarm bells could not have rung louder on Wednesday. Figures showed U.S. private sector employment growth in May was the slowest in more than two years, perhaps an ominous signal for Friday's non-farm payroll report. Meanwhile, the services sector contracted in May for the first time in nearly a year and input prices paid by businesses leaped to their highest in two and a half years. If gold prices took their cue from the 'flation' side of those numbers, the bond market took its cue from the 'stag' side of the equation. Treasuries prices rallied strongly, and the 10-year yield posted its biggest fall since mid-April. Trump used the weak economic data to take to social media and repeat his call for Fed Chair Jerome 'Too Late' Powell to lower interest rates, complaining that "Europe" has already cut rates nine times. If he's referring to the European Central Bank, that's not quite accurate. The ECB has cut rates seven times since June last year, but is widely expected to make that eight on Thursday. The Bank of Canada took a leaf out of the Fed's book on Wednesday, deciding against cutting interest rates and choosing to wait and see what the effects of U.S. trade policy are. It said another rate cut might be needed, however, if the economy slows sufficiently. Aside from the ECB, the biggest market-moving event on Thursday could be China's 'unofficial' services sector PMI report for May. Signs of renewed weakness might be the cue for a 'risk-off' tone to world markets on Thursday, although the evidence of Wednesday shows that's no guarantee. Disinflation is a greater force right now than inflation Investors, consumers and policymakers may justifiably fear the specter of tariff-fueled inflation later this year and beyond, but it's powerful global disinflationary forces that are weighing most heavily right now. The OECD said on Tuesday it expects collective annual headline inflation in G20 economies to moderate to 3.6% this year from 6.2% last year, cooling further in 2026 to 3.2%. But the United States is an "important exception," the OECD argues, and it sees inflation there rising to just under 4% later this year and remaining above target in 2026. While annual PCE consumer inflation in the U.S. cooled to 2.1% in April, the slowest rate in four years and virtually at the Fed's 2% target, consumer inflation expectations are the loftiest in decades. The Fed has paused its easing cycle as a result, and U.S. bond yields are higher than most of their G10 peers. Economists at Goldman Sachs share the OECD's view that U.S. inflation will pick up to near 4% this year, with tariffs accounting for around half of that. Many others also agree that the U.S. appears to be the exception, not the rule. The world's next two largest economies, China and the euro zone, find themselves trying to stave off disinflation. Deepening trade and financial ties between the two may only intensify these forces, keeping a lid on price increases. SPECTER OF DEFLATION Annual inflation in the euro zone cooled to 1.9% in May, below the European Central Bank's 2% target, essentially setting the seal on another quarter-point rate cut later this week. More easing appears to be in the cards. As economists at Nomura point out, inflation swaps are priced for inflation undershooting the ECB's target for at least the next two years. This, combined with weakening growth due to U.S. tariffs and disinflationary pressure from China, could force the ECB to cut rates another 50 basis points to 1.5% by September. China's war on deflation is, of course, well-known to investors, but it has appeared to slip off their collective radar given how protracted it has become. The last time annual inflation in China eclipsed 1% was more than two years ago, and it has remained near zero, on average, ever since. China's 10-year bond yield remains anchored near January's record low below 1.60%, reflecting investors' skepticism that price pressures will accelerate any time soon. They have reason to be doubtful. Deflation and record-low bond yields continue to stalk the economy despite Beijing's fiscal and monetary stimulus efforts since September. And punitive tariffs on exports to the U.S., one of its largest export markets, are generating massive uncertainty about the country's economic outlook moving forward. REER-VIEW MIRROR This is where the exchange rate becomes important. On the face of it, Beijing appears to have resisted mounting pressure on the yuan thus far, with the onshore and offshore yuan last week trading near their strongest levels against the dollar since November. But when considering the yuan's broad real effective exchange rate (REER), an inflation-adjusted measure of its value against a basket of currencies, the Chinese currency is the weakest since 2012. Robin Brooks at The Brookings Institution reckons it may be undervalued by more than 10%. With China's goods so cheap in the global marketplace, China is essentially exporting deflation. And the yuan's relative weakness could put pressure on other Asian countries to weaken their currencies to keep them competitive, even as the Trump administration potentially encourages these governments to do the exact opposite. Countries in Asia and around the world, especially in the euro zone, may also be nervous that China could dump goods previously bound for the U.S. on their markets. If anyone wants confirmation that the "tariffs equal inflation" view is too simplistic, they got it this week from Switzerland, where deflation is back and potential negative interest rates may not be far behind. True, Trump's threatened tariffs could throw everything up in the air. But the Swiss example is a warning to markets and policymakers that global disinflationary forces may be spreading. What could move markets tomorrow? * Australia trade (April) * South Korea GDP (Q1, revised) * China Caixin services PMI (May) * European Central Bank interest rate decision * Canada trade (April) * Canada PMI (May) * U.S. weekly jobless claims * U.S. trade (April) * Fed officials speaking at various events include: FedGovernor Adriana Kugler, Kansas City Fed President JeffreySchmid, and Philadelphia Fed President Patrick Harker Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias. (By Jamie McGeever; Editing by Nia Williams) Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
Is TJX's 5% Drop Post Q1 Earnings a Caution or Opportunity?
The TJX Companies, Inc. TJX saw its shares drop 5% following the release of its first-quarter fiscal 2026 results on May 21, 2025. This performance marks a notable underperformance compared to the Zacks Retail - Discount Stores industry, the Zacks Retail and Wholesale sector, which slipped 1% and 0.5%, respectively, and the broader S&P 500, which advanced 0.2% during the same period. Image Source: Zacks Investment Research The TJX Companies has delivered relatively lower stock performance compared to some other major players in the discount retail sector, such as Dollar General Corporation DG, Dollar Tree DLTR and Costco Wholesale Corporation COST. During the same period, Dollar General Corporation, Dollar Tree and Costco Wholesale Corporation posted gains of 10.2%, 6.8% and 1.9%, the pullback in TJX shares came despite the company surpassing expectations on both the top and bottom lines. Its fiscal first-quarter results exceeded the Zacks Consensus Estimate for earnings and revenue, reflecting continued strength in customer traffic and solid comparable store sales across all divisions. Interestingly, the stock was trading near record levels ahead of the earnings release. Trading at $128.12 as of June 3, TJX shares are down 5.7% from their 52-week high of $135.85, which was reached on May 20, just a day before the earnings divergence between solid earnings performance and stock price weakness raises a critical question for investors: Is the pullback a short-term overreaction or a long-term buying opportunity? The TJX Companies reported a strong start to fiscal year 2026, demonstrating solid performance across all divisions. Growth was broad-based, fueled by an increase in customer traffic in both U.S. and international markets. As a result, net sales reached $13,111 million, marking a 5% year-over-year increase, consistent on a constant currency basis. Consolidated comparable store sales rose 3%, primarily driven by higher customer transactions. However, earnings per share (EPS) were 92 cents per share, down from 93 cents reported in the year-ago down the performance by segment, comparable store sales grew 2% at Marmaxx (U.S.), 4% at HomeGoods (U.S.), 5% at TJX Canada, and 5% at TJX International (Europe and Australia). Comparable sales increased in both apparel and home categories, underscoring TJX's effective strategy and positioning the company for long-term sustainability with a focus on driving customer transactions. On its last earnings call, TJX highlighted a strong start to the fiscal second quarter and reaffirmed its focus on executing the core fundamentals of its off-price retail model. Management remains confident that the company's broad and compelling assortments, coupled with a resilient business model, will continue to attract value-conscious shoppers, even amid ongoing macroeconomic challenges and tariff-related company expects consolidated comparable store sales growth of 2% to 3% for the fiscal second quarter. Quarterly EPS are projected to range between 97 cents and $1.00, indicating a 1% to 4% increase compared to 96 cents in the prior year's period. For the full fiscal year 2026, TJX anticipates comparable store sales growth of 2% to 3%, consolidated sales to be in the range of $58.1 billion to $58.6 billion, up 3% to 4% with EPS forecasted between $4.34 and $4.43, an increase of 2% to 4% from the previous year's $4.26. TJX Companies remains upbeat about its long-term prospects, grounded in a strong business model and a proven ability to adapt through various retail and economic cycles. The company credits its resilience to the flexibility of its off-price model, the experience of its leadership team, and a well-established global buying network that taps into a wide range of vendors the heart of TJX's strategy is its value proposition, delivering a compelling mix of brand, fashion, quality, and price, which continues to attract a broad and diverse customer base. This broad appeal is supported by a carefully curated mix of brands that sustain steady traffic. Backed by a flexible, global buying and supply chain model and a unique treasure-hunt shopping experience, it remains well-equipped to adapt to changing consumer preferences and capture market share in both stable and challenging economic has also benefited from solid growth in both its physical stores and e-commerce channels. The company is rapidly expanding its footprint in the United States, Europe, Canada, and Australia. In the first quarter of fiscal 2026 alone, TJX added 36 new stores, ending the quarter with a total of 5,121 locations. Further, with an increasing number of consumers resorting to online shopping, The TJX Companies has undertaken several initiatives to boost online sales and strengthen its e-commerce business. The TJX Companies is currently trading at a notable discount compared to its industry peers, making it an appealing option for value-focused investors. As of now, TJX trades at a forward 12-month price-to-earnings (P/E) ratio of 27.75X, which is significantly lower than the industry average of 34.17X. While its valuation is lower than that of Costco Wholesale Corporation, which trades at a significantly higher 54.42X, it remains above other discount retail peers such as Dollar General Corporation and Dollar Tree, which have P/E ratios of 19.48X and 17.89X, respectively. Image Source: Zacks Investment Research The TJX Companies is also trading well above its 50-day and 200-day moving averages, an important bullish technical indicator. This breakout is not just technical but reflects growing market confidence in its growth story. Despite its strengths, TJX faces several challenges that could impact its near-term performance. Rising operating costs, driven by inflationary pressures and wage increases, may put pressure on margins despite ongoing efforts to manage expenses. Additionally, continued trade tensions and tariffs on imports from China and other countries remain a concern, while foreign exchange headwinds could further weigh on of the key near-term risks for TJX is the impact of tariffs on both direct and indirect imports into the U.S. Management expects these pressures to weigh on fiscal second-quarter performance, with gross margin projected to decline by 40 basis points (bps) year over year to 30%. Despite mitigation strategies like pricing adjustments and sourcing shifts, the company forecasts a full-year gross margin contraction of 10 to 20 bps, which could strain profitability even if sales remain TJX's international operations make it vulnerable to currency fluctuations. Management anticipates foreign exchange headwinds will reduce pretax profit margin by 10 to 20 basis points in fiscal 2026, presenting further risks to overall performance. Reflecting cautious sentiment around The TJX Companies, the Zacks Consensus Estimate for EPS has seen downward revisions. Over the past 30 days, the consensus estimate has declined 2 cents to $1.00 for the current quarter and a cent to $4.46 for the fiscal year, respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Image Source: Zacks Investment Research Following the post-earnings dip, The TJX Companies presents a mixed picture for investors. While the company delivered better-than-expected results in the fiscal first quarter, driven by solid customer traffic and broad-based sales growth, external headwinds continue to weigh on sentiment. Inflationary cost pressures, rising wages, tariffs and currency fluctuations are expected to pressure margins in the near term. Additionally, recent downward revisions in earnings estimates reflect growing investor caution. That said, TJX's resilient off-price model, strong global footprint, and consistent execution provide a solid foundation for long-term growth. With shares trading at a reasonable valuation relative to peers, investors may consider holding the stock as the company navigates short-term challenges. As macro conditions stabilize and cost pressures ease, TJX could be well-positioned to regain TJX Companies carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The TJX Companies, Inc. (TJX) : Free Stock Analysis Report Dollar General Corporation (DG) : Free Stock Analysis Report Dollar Tree, Inc. (DLTR) : Free Stock Analysis Report Costco Wholesale Corporation (COST) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell?
Exelixis EXEL has performed well this year. Shares of the biotech company have gained 28.1% year to date against the industry's decline of 3.5%. The stock has outperformed the sector and the S&P 500 Index in this timeframe. Image Source: Zacks Investment Research The company's upbeat performance can be attributed to its strong quarterly results, raised guidance, label expansion of Cabometyx (cabozantinib) and efforts to increase shareholders' returns. In March, the FDA expanded Cabometyx's label for patients with previously treated advanced neuroendocrine tumors (NET). Let's delve deeper and analyze the company's strengths and weaknesses to make an informed decision on the stock. Exelixis' lead drug Cabometyx maintains its status as the leading tyrosine kinase inhibitor (TKI) for the treatment of renal cell carcinoma (RCC) in both the frontline immuno-oncology (IO) +TKI market and the second-line monotherapy segment. Cabometyx is also approved for use in combination with Bristol Myers' BMY Opdivo in the first-line setting in RCC. Demand has been strong for this combination, boosting sales. BMY's Opdivo is one of the leading IO drugs, and has been approved for various oncology indications. Cabometyx is also approved for the treatment of hepatocellular carcinoma. Given the strong momentum of Cabometyx in the first quarter, EXEL raised its annual guidance for net product revenues and total revenues by $100 million. The recent label expansion of cabozantinib for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NET (pNET) and those with previously treated advanced extra-pancreatic NET should further fuel sales. Cabometyx is now the first and only systemic treatment that is FDA approved for previously treated NET regardless of primary tumor site, grade, somatostatin receptor expression and functional status. The pipeline progress has been impressive as well, as Exelixis looks to expand its oncology portfolio beyond Cabometyx. The company is now focused on developing zanzalintinib, a next-generation oral TKI. Results from an expansion cohort of the phase Ib/II STELLAR-001 study evaluating zanzalintinib alone or in combination with Tecentriq (atezolizumab) in patients with previously treated metastatic colorectal cancer (CRC) were encouraging. Results showed that all efficacy parameters, including objective response rate, PFS and overall survival, favored the combination of zanzalintinib plus Tecentriq versus zanzalintinib monotherapy in the overall population as well as in a subgroup of patients without liver metastases. The data support zanzalintinib's ongoing pivotal development in metastatic CRC. Meanwhile, Exelixis collaborated with pharma giant Merck MRK to evaluate zanzalintinib in combination with its blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) in a late-stage study for treating patients with head and neck squamous cell carcinoma (HNSCC). Per the terms of the agreement, Merck is supplying Keytruda for the ongoing, Exelixis-sponsored phase III STELLAR-305 study in previously untreated PD-L1-positive recurrent or metastatic HNSCC. In April, Exelixis presented preclinical data from four pipeline candidates. Data on XL309, XB628 and XB371 were encouraging. Exelixis is on track to submit an investigational new drug application (IND) application for XB371 to the FDA in 2025. The successful development of additional drugs should broaden its portfolio and reduce its dependence on its lead drug, Cabometyx. Exelixis is also making efforts to increase shareholder value through repurchases. In August 2024, the board authorized a stock repurchase program to acquire up to $500 million of the company's common stock before Dec. 31, 2025. In February 2025, another share buyback program for an additional $500 was authorized. Under these programs, as of March 31, 2025, Exelixis repurchased $494.5 million of the company's common stock. From a valuation standpoint, EXEL is expensive. Going by the price/sales ratio, its shares currently trade at 4.75x forward sales, higher than its mean of 3.64x and the biotech industry's 1.69x. Image Source: Zacks Investment Research The bottom-line estimate for 2025 has risen from $2.31 to $2.57, while that for 2026 has increased to $3.02 from $2.85 over the past 30 days. Image Source: Zacks Investment Research Large biotech companies are generally considered safe havens for investors interested in this sector. Exelixis' lead drug, Cabometyx, maintains momentum for the company. The label expansion of Cabometyx should boost its growth. The company's efforts to expand its portfolio are encouraging as well. The successful development of additional drugs should broaden its portfolio and reduce its dependence on its lead drug. The company's efforts to increase shareholder value are impressive and should boost returns. EXEL is a good stock to buy now, considering its good fundamentals and growth prospects. We recommend the stock to investors as we believe there is more room for growth. EXEL currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Exelixis, Inc. (EXEL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data